Abstract: The present disclosure provides compositions comprising IFNE and methods of using the same to treat cancer and/or enhancing responsiveness to immune checkpoint blockade therapy in a patient in need thereof. Also disclosed herein are compositions including tandem bicistronic expression cassettes, and methods of using the same to generate large genomic deletions and/or knock-in gene alterations.

Abstract: The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.

Abstract: The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.

Abstract: Devices, systems and methods are provided for controlling the operation of a breathing assistance device for a user. The controller may include an input for receiving sensor data to measure at least one airflow parameter of the user's airflow; a memory unit that stores at least one machine learning model and at least one classifier or predictor; and a processor that is configured to perform measurements and to generate a control signal for adjusting the operation of the breathing assistance device for a current monitoring time period by: obtaining measured air pressure and/or airflow data and measured FOT data during a current monitoring time period; performing feature extraction on the measured data to obtain feature values that are used by the machine learning model employed by the at least one classifier or predictor to determine a property of the user; and adjusting the control signal based on the determined property.

Abstract: The present technology relates generally to methods and compositions for treating, preventing, and/or ameliorating p53-mutant cancers in a subject in need thereof, including acute myeloid leukemia (AML), pancreatic cancer, and liver cancer, by administration of a therapeutically effective amount of a 2-oxoglutarate dehydrogenase (OGDH) inhibitor.

Abstract: Devices, systems and methods are provided for controlling the operation of a breathing assistance device for a user. The controller may include an input for receiving sensor data to measure at least one airflow parameter of the user's airflow; a memory unit that stores at least one machine learning model and at least one classifier or predictor; and a processor that is configured to perform measurements and to generate a control signal for adjusting the operation of the breathing assistance device for a current monitoring time period by: obtaining measured air pressure and/or airflow data and measured FOT data during a current monitoring time period; performing feature extraction on the measured data to obtain feature values that are used by the machine learning model employed by the at least one classifier or predictor to determine a property of the user; and adjusting the control signal based on the determined property.

Abstract: The present disclosure relates generally to compositions and methods for the treatment of a RAS-mutant cancer. In particular, the present technology relates to administering a therapeutically effective amount of one or more TXNRD1 inhibitors to a subject diagnosed with, or at risk for a RAS-mutant cancer (e.g., RAS-mutant pancreatic cancer).

Abstract: The present disclosure relates generally to compositions and methods for treating or ameliorating acute myeloid leukemia in a subject in need thereof. In particular, the present disclosure provides a method comprising administering to a subject a therapeutically effective amount of at least one agent that suppresses Trim28 activity.

Abstract: Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a uPAR-specific chimeric antigen receptor. Also disclosed herein are methods for using the engineered immune cells of the present technology to treat or ameliorate the effects of cancer and senescence-associated pathologies (e.g., lung fibrosis, atherosclerosis, Alzheimer's disease, diabetes, liver fibrosis, chronic kidney disease, aging, or osteoarthritis) by selectively targeting senescent cells. Also provided herein are methods for detecting the senescent cell burden in a patient.

Abstract: The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.

Abstract: The present disclosure relates generally to methods for ameliorating or treating acute myeloid leukemia (AML). In particular, the present technology relates to administering a therapeutically effective amount of one or more compositions that inhibit the vitamin B6 pathway to a subject diagnosed with, or at risk for AML.

Abstract: A multi-tenant virtual network-aware storage array device is disclosed and includes a storage array manager component for storing and managing data associated with a plurality of tenants. The storage array manager component is configured to provide a plurality of storage entities, where each of the plurality of storage entities is associated with a tenant of the plurality of tenants. The storage array manager component generates a virtual network instance (“VNI”) for a first tenant, where the VNI is associated with a first storage entity and with a virtual network identifier (“VNID”) identifying the VNI. In addition, a virtual network tunnel endpoint (“VTEP”) for the VNI is generated. The storage array manager component encapsulates content relating to the first storage entity with the VNID for presentation to a first tenant system of the first tenant over a transport network via the VTEP.

Abstract: An attenuator for optical signals includes a base. A first ferrule has a first optic fiber passing through a central bore therein and attached to a first lens at an end of the first ferrule. The first ferrule is fixed in position relative to the base. A second ferrule has a second optic fiber passing through a central bore therein and attached to a second lens at an end of the second ferrule. The second lens faces the first lens. The second ferrule is fixed to the base and can be moved relative to the base by a user adjustment feature, so that the second lens may be moved relative to the first lens. The relative placement between the first and second lens controls the attenuation of the attenuator.

Abstract: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.

Abstract: The invention provides the components of in vivo and in vitro systems and methods which use them to study the effects of altered expression of a gene activity, such as the human akt, bcl-2, eIF4E or PTEN activities, on the descendants of stem cells that have been engineered to give rise to hematopoietic tumorigenic or tumor cells, such as lymphomas, with a high frequency. The present invention provides vectors, cells and mammals, and methods which in part depend on such products, useful for understanding tumorigenesis and its treatments, and in particular, for identifying and studying inhibitors and activators associated with tumor cell growth and growth inhibition, cell death through apoptotic pathways, and changes in apoptotic pathway components that affect drug sensitivity and resistance in tumorigenic cells.

Abstract: This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal.